NCT06924658

Metformin in Safety and Efficacy in Gouty Patients

the Impact of Metformin Use on Clinical Outcomes in Gouty Patients

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Mostafa Bahaa · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Conditions

• Gout

Interventions

Type	Name	Description
OTHER	placebo	Placebo will have the same look of metformin
DRUG	Metformin	Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients

Timeline

• Start date: 2025-04-20
• Primary completion: 2026-11-20
• Completion: 2026-11-20
• First posted: 2025-04-11
• Last updated: 2025-06-27

Locations

1 site across 1 country: Egypt